Advertisement

Reactions Weekly

, Volume 1719, Issue 1, pp 20–20 | Cite as

Alemtuzumab/fingolimod/methylprednisolone

Unexpected high multiple sclerosis and lack of efficacy: case report
Case report
  • 15 Downloads

Reference

  1. Bernard-Valnet R, et al. Unexpected high multiple sclerosis activity after switching from fingolimod to alemtuzumab. Multiple Sclerosis and Related Disorders 25: 216-218, Oct 2018. Available from: URL: http://doi.org/10.1016/j.msard.2018.08.006 - France

Copyright information

© Springer Nature Switzerland AG 2018

Personalised recommendations